Citations

Showing 10 of 108081 citations.

Anatomical Step-by-Step Dissection of Complex Skull Base Approaches for Trainees: Surgical Anatomy of the Endoscopic Endonasal Middle-Inferior Clivectomy, Odontoidectomy, and Far-Medial Approach
Alexander, A. Yohan , Leonel, Luciano, Gompel, Jamie J. Van , Link, Michael J., Peris-Celda, Maria, Van Gompel, Jamie J , Agosti, Edoardo , Alexander, A Yohan , Choby, Garret , Pinheiro‐Neto, Carlos , Peris‐Celda, Maria

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 22, 2023 | Volume: 85 | Issue: 05 | Pages: 526-539

10.1055/a-2114-4660 | PMID 39228882 Get It

Abstract Introduction The clival, paraclival, and craniocervical junction regions are challenging surgical targets. To approach these areas, endoscopic endonasal transclival approaches (EETCAs) and their extensions (far-medial approach and odontoidectomy) have gained popularity as they obviate manipulating and working between neurovascular structures. Although several cadaveric studies have further refined these contemporary approaches, few provide a detailed step-by-step description. Thus, we aim to didactically describe the steps of the EETCAs and their extensions for trainees. Methods Six formalin-fixed cadaveric head specimens were dissected. All specimens were latex-injected using a six-vessel technique. Endoscopic endonasal middle and inferior clivectomies, far-medial approaches, and odontoidectomy were performed. Results Using angled endoscopes and surgical instruments, an endoscopic endonasal midclivectomy and partial inferior clivectomy were performed without nasopharyngeal tissue disruption. To complete the inferior clivectomy, far-medial approach, and partially remove the anterior arch of C1 and odontoid process, anteroinferior transposition of the Eustachian–nasopharynx complex was required by transecting pterygosphenoidal fissure tissue, but incision in the nasopharynx was not necessary. Full exposure of the craniocervical junction necessitated bilateral sharp incision and additional inferior mobilization of the posterior nasopharynx. Unobstructed access to neurovascular anatomy of the ventral posterior fossa and craniocervical junction was provided. Conclusion EETCAs are a powerful tool for the skull-base surgeon as they offer a direct corridor to the ventral posterior fossa and craniocervical junction unobstructed by eloquent neurovasculature. To facilitate easier understanding of the EETCAs and their extensions for trainees, we described the anatomy and surgical nuances in a didactic and step-by-step fashion.
Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Rades, Dirk , Zwaan, Inga, Soror, Tamer , Idel, Christian, Pries, Ralph , BRUCHHAGE, KARL L., Hakim, Samer G. , Yu, Nathan Y.

Mayo Clinic

Cancers | June 22, 2023 | Volume: 15 | Issue: 13 | Pages: 3278

10.3390/cancers15133278 | PMID 37444388 Get It

Cisplatin is the standard for the chemoradiation of squamous cell carcinoma of the head and neck (HNSCC). Many patients cannot receive cisplatin due to impaired renal function. This study investigated carboplatin as an alternative option. In total, 131 patients assigned to two courses of cisplatin (20 mg/m2/d1-–5 or 25 mg/m2/d1–4) were matched to 45 patients not suitable for cisplatin and receiving carboplatin (AUC 1.0/d1–5 or AUC 1.5/d1–4). The endpoints included loco-regional control (LRC), metastases-free survival (MFS), overall survival (OS), toxicities, and the completion of chemotherapy. The patients in the carboplatin group were significantly older and had more G3 tumors. Otherwise, the baseline characteristics were balanced. The LRC rates at 2 and 3 years were 77% and 76% in the cisplatin group vs. 69% and 65% in the carboplatin group (p = 0.21). The MFS rates were 83% and 78% vs. 78% and 74% (p = 0.34) and the OS rates 83% and 79% vs. 83% and 75% (p = 0.64), respectively. The outcomes were not significantly different in the subgroups receiving definitive or adjuvant chemoradiation. No significant differences were found regarding toxicities. Non-significantly more patients in the carboplatin group completed their chemotherapy (78% vs. 66%, p = 0.15). Carboplatin was associated with similar outcomes and toxicities as cisplatin, although these patients had worse renal function, more aggressive tumors, and were older. Given the limitations of this study, carboplatin appears an option for patients not suitable for cisplatin.
Creation and Initial Validation of the Mayo Outpatient Precepting Evaluation Tool
Paulson, Deirdre , Nordin, Terri , Hidaka, Brandon H.

Mayo Clinic

Family Medicine | June 21, 2023 | Volume: 55 | Issue: 8 | Pages: 544-549

10.22454/fammed.2023.164770 | PMID 37696025 Get It

Background and Objectives: Preceptors in family medicine residencies need feedback to improve. When we found no validated, behavior-based tool to assess the outpatient precepting of family medicine residents, we sought to fill this gap by developing and initially validating the Mayo Outpatient Precepting Evaluation Tool (MOPET). Methods: To develop the MOPET, we applied the Stanford Faculty Development Program (SFDP) theoretical framework for education, more recent work on peer review of medical teaching, and expert review of items. The residency behavioral scientist and a volunteer physician independently completed the MOPET while co-observing a precepting physician during continuity clinic sessions (N=20). We assessed the tool’s validity via interrater reliability and cross-validation with the SFDP-26. Results: The tool demonstrated high interrater reliability for the following effective teaching behaviors: (a) allowing the resident to present without interrupting, (b) encouraging the formulation of a goal, (c) checking in on the resident’s goal, (d) using multimodal teaching aids, (e) asking to discuss the differential diagnosis, (f) asking to discuss alternative management, (g) encouraging the resident to pursue literature and/or other resources, and (h) reinforcing self-directed learning. The MOPET measures strongly correlated with most items from the SFDP-26, indicating good cross-validity. Conclusions: The MOPET is a theoretically sound, behavior-based, reliable, and initially validated tool for peer review of outpatient family medicine resident teaching. This tool can support faculty development in outpatient clinical learning environments.
End Point Considerations for Clinical Trials in Enteric Hyperoxaluria
Langman, Craig B. , Assimos, Dean G. , Blank, Melanie , Calle, Juan , Grauer, Andreas , Kausz, Annamaria, Milliner, Dawn S. , Nazzal, Lama , Smith, Kimberly , Tasian, Gregory E. , Thompson, Aliza, Wood, Kyle D. , Worcester, Elaine M. , Yang, Sixun, Malley, Meaghan A., Knauf, Felix , Assimos, Dean , Milliner, Dawn , Tasian, Greg , Worcester, Elaine , Lieske, John C , Knauf, Felix , Lieske, John C.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | June 21, 2023 | Volume: 18 | Issue: 12 | Pages: 1637-1644

10.2215/cjn.0000000000000234 | PMID 37342976 Get It

Enteric hyperoxaluria is a medical condition characterized by elevated urinary oxalate excretion due to increased gastrointestinal oxalate absorption. Causative features include fat malabsorption and/or increased intestinal permeability to oxalate. Enteric hyperoxaluria has long been known to cause nephrolithiasis and nephrocalcinosis, and, more recently, an association with CKD and kidney failure has been shown. Currently, there are no US Food and Drug Administration–approved therapies for enteric hyperoxaluria, and it is unclear what end points should be used to evaluate the efficacy of new drugs and biologics for this condition. This study represents work of a multidisciplinary group convened by the Kidney Health Initiative to review the evidence supporting potential end points for clinical trials in enteric hyperoxaluria. A potential clinical outcome is symptomatic kidney stone events. Potential surrogate end points include ( 1 ) an irreversible loss of kidney function as a surrogate for progression to kidney failure, ( 2 ) asymptomatic kidney stone growth/new stone formation observed on imaging as a surrogate for symptomatic kidney stone events, ( 3 ) urinary oxalate and urinary calcium oxalate supersaturation as surrogates for the development of symptomatic kidney stone events, and ( 4) plasma oxalate as a surrogate for the development of the clinical manifestations of systemic oxalosis. Unfortunately, because of gaps in the data, this Kidney Health Initiative workgroup was unable to provide definitive recommendations. Work is underway to obtain robust information that can be used to inform trial design and medical product development in this space.
Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma
Levin, Solomon , Tomasini, Michael D. , Knox, James , Shirani, Mahsa , Shebl, Bassem , Requena, David , Clark, Jackson, Heissel, Søren , Alwaseem, Hanan , Surjan, Rodrigo C. , Lahasky, Ron, Molina, Henrik , Lyons, Barbara A. , Migler, Rachael D. , Levin, Solomon N , Surjan, Rodrigo , Torbenson, Michael S , Lyons, Barbara , Migler, Rachael D , Coffino, Philip , Simon, Sanford M , Requena, David , Torbenson, Michael , Simon, Sanford M.

Mayo Clinic

Science Advances | June 21, 2023 | Volume: 9 | Issue: 25 | Pages: No page available

10.1126/sciadv.adg7038 | PMID 37343102 Get It

Fibrolamellar hepatocellular carcinoma (FLC) is a usually lethal primary liver cancer driven by a somatic dysregulation of protein kinase A. We show that the proteome of FLC tumors is distinct from that of adjacent nontransformed tissue. These changes can account for some of the cell biological and pathological alterations in FLC cells, including their drug sensitivity and glycolysis. Hyperammonemic encephalopathy is a recurrent problem in these patients, and established treatments based on the assumption of liver failure are unsuccessful. We show that many of the enzymes that produce ammonia are increased and those that consume ammonia are decreased. We also demonstrate that the metabolites of these enzymes change as expected. Thus, hyperammonemic encephalopathy in FLC may require alternative therapeutics.
Fentanyl-Associated Overdose Deaths Outside the Hospital
Jeffery, Molly M. , Stevens, Maria , D’Onofrio, Gail , Melnick, Edward R. , Jeffery, Molly Moore , Melnick, Edward R

Mayo Clinic

New England Journal of Medicine | June 21, 2023 | Volume: 389 | Issue: 1 | Pages: 87-88

10.1056/nejmc2304991 | PMID 37342960 Get It

Five hats of effective leaders: teacher, mentor, coach, supervisor and sponsor
Winters, Richard C. , Chan, Teresa M. , Barth, Bradley E.

Mayo Clinic

BMJ Leader | June 21, 2023 | Volume: 8 | Issue: 1 | Pages: 9-14

10.1136/leader-2022-000733 | PMID 37344163 Get It

Background/aim Teaching, mentoring, coaching, supervising and sponsoring are often conflated in the literature. In this reflection, we clarify the distinctions, the benefits and the drawbacks of each approach. We describe a conceptual model for effective leadership conversations where leaders dynamically and deliberately ‘wear the hats’ of teacher, mentor, coach, supervisor and/or sponsor during a single conversation. Methods As three experienced physician leaders and educators, we collaborated to write this reflection on how leaders may deliberately alter their approach during dynamic conversations with colleagues. Each of us brings our own perspective and lens. Results We articulate how each of the ‘five hats’ of teacher, mentor, coach, supervisor and sponsor may help or hinder effectiveness. We discuss how a leader may ‘switch’ hats to engage, support and develop colleagues across an ever-expanding range of contexts and settings. We demonstrate how a leader might ‘wear the five hats’ during conversations about career advancement and burn-out. Conclusion Effective leaders teach, mentor, coach, supervise and sponsor during conversations with colleagues. These leaders employ a deliberate, dynamic and adaptive approach to better serve the needs of their colleagues at the moment.
The Reviewer Academy of the Society of Critical Care Medicine: Key Principles and Strategic Plan
Aslakson, Rebecca A. , Frazee, Erin N. , Meissen, Heather , Morrow, Brenda M., Nazer, Lama , Branson, Richard D. , Mayer, Kirby P. , Napolitano, Natalie , Lane‐Fall, Meghan B. , John, Preeti R. , Dellinger, R. Phillip, Parker, Margaret M. , Argent, Andrew C. , Boateng, Adjoa , Green, Thomas P. , Kudchadkar, Sapna R. , Checchia, Paul A. , Alexander, Peta , Lee, Jan Hau , Morrow, Brenda May , Sikora, Andrea , Maslove, David M. , Rech, Megan A. , Sorce, Lauren R. , Tasker, Robert C. , Buchman, Timothy G.

Mayo Clinic

Critical Care Medicine | June 21, 2023 | Volume: 51 | Issue: 9 | Pages: 1111-1123

10.1097/ccm.0000000000005962 | PMID 37341529 Get It

The Society of Critical Care Medicine (SCCM) Reviewer Academy seeks to train and establish a community of trusted, reliable, and skilled peer reviewers with diverse backgrounds and interests to promote high-quality reviews for each of the SCCM journals. Goals of the Academy include building accessible resources to highlight qualities of excellent manuscript reviews; educating and mentoring a diverse group of healthcare professionals; and establishing and upholding standards for insightful and informative reviews. This manuscript will map the mission of the Reviewer Academy with a succinct summary of the importance of peer review, process of reviewing a manuscript, and the expected ethical standards of reviewers. We will equip readers to target concise, thoughtful feedback as peer reviewers, advance their understanding of the editorial process and inspire readers to integrate medical journalism into diverse professional careers.
Failure of mecA/mecC PCR Testing to Accurately Predict Oxacillin Resistance in a Patient with Staphylococcus aureus Infective Endocarditis
Hess, Kyle A., Kooda, Kirstin , Shirley, Joshua D. , Schuetz, Audrey N. , Saleh, Omar Abu , Stevens, Ryan W. , Abu Saleh, Omar , Schuetz, Audrey N , Stevens, Ryan W

Mayo Clinic

Antimicrobial Agents and Chemotherapy | June 21, 2023 | Volume: 67 | Issue: 10 | Pages: No page available

10.1128/aac.00437-23 | PMID 37341623 Get It

Genotypic testing for mecA / mecC is heavily relied upon for rapid optimization of antimicrobial therapy in infections due to Staphylococcus aureus . Little is known regarding optimal reporting and/or therapy for patients demonstrating lack of genotypic evidence of mecA or mecC but phenotypic oxacillin resistance.
The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer
Qin, Xuanzi , Sharma, Vidit , Boorjian, Stephen A. , Barocas, Daniel A. , Dusetzina, Stacie B. , Moses, Kelvin A. , Joyce, Daniel D , Dusetzina, Stacie , Joyce, Daniel

Mayo Clinic

Journal of Urology | June 21, 2023 | Volume: 210 | Issue: 3 | Pages: 447-453

10.1097/ju.0000000000003592 | PMID 37341420 Get It